skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Eltrombopag – a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations

Review

(2772) Views  (1007) Full article downloads

Authors: Lucy Cook, Nichola Cooper

Published Date June 2010 Volume 2010:4 Pages 139 - 145
DOI: http://dx.doi.org/10.2147/DDDT.S8601

Lucy Cook, Nichola Cooper

Department of Haematology, Imperial Health Care NHS Trust, Hammersmith Hospital, London, UK

Abstract: Eltrombopag is one of a number of novel agents recently developed for use in the treatment of patients with immune thrombocytopenia (ITP). Rather than preventing destruction of platelets, these agents increase the production of platelets, presumably overwhelming the immune system resulting in normal platelet counts in individuals refractory to or dependent on other therapies. These treatments are well tolerated and in randomized controlled trials show an improvement in platelet counts and a reduction in bleeding in refractory patients. This article summarizes the development of this new class of drug and evaluates the safety and efficacy of eltrombopag in patients with ITP.

Keywords: eltrombopag, immune thrombocytopenic purpura, thrombopoietin








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The pathophysiology of bronchiectasis
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
Health literacy and health seeking behavior among older men in a middle-income nation
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Zinc oxide nanoparticles as selective killers of proliferating cells
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University